Stryker (NYSE:SYK) was upgraded by investment analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a report released on Tuesday, The Fly reports.
Other equities research analysts also recently issued reports about the stock. Cowen set a $160.00 price target on shares of Stryker and gave the company a “buy” rating in a research note on Friday, October 6th. Robert W. Baird upgraded shares of Stryker from a “neutral” rating to an “outperform” rating in a research note on Friday, November 24th. Barclays raised their price target on shares of Stryker from $137.00 to $148.00 and gave the company an “underweight” rating in a research note on Friday, October 27th. Zacks Investment Research upgraded shares of Stryker from a “sell” rating to a “hold” rating in a research note on Tuesday, October 24th. Finally, ValuEngine downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $154.20.
Shares of Stryker (NYSE SYK) opened at $154.84 on Tuesday. Stryker has a one year low of $116.50 and a one year high of $160.62. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63. The firm has a market cap of $57,946.95, a P/E ratio of 33.09, a PEG ratio of 2.44 and a beta of 0.78.
In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total transaction of $776,700.00. Following the completion of the transaction, the insider now owns 83,207 shares in the company, valued at approximately $12,925,375.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.40% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. Coldstream Capital Management Inc. increased its stake in shares of Stryker by 3.7% in the 2nd quarter. Coldstream Capital Management Inc. now owns 17,445 shares of the medical technology company’s stock valued at $2,421,000 after acquiring an additional 626 shares in the last quarter. Retirement Systems of Alabama increased its stake in shares of Stryker by 2.5% in the 3rd quarter. Retirement Systems of Alabama now owns 234,870 shares of the medical technology company’s stock valued at $33,356,000 after acquiring an additional 5,656 shares in the last quarter. Lockheed Martin Investment Management Co. bought a new stake in shares of Stryker in the 2nd quarter valued at $1,249,000. Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its stake in shares of Stryker by 444.7% in the 2nd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 165,225 shares of the medical technology company’s stock valued at $19,667,000 after acquiring an additional 134,892 shares in the last quarter. Finally, Ngam Advisors L.P. increased its stake in shares of Stryker by 217.3% in the 2nd quarter. Ngam Advisors L.P. now owns 77,132 shares of the medical technology company’s stock valued at $9,243,000 after acquiring an additional 52,821 shares in the last quarter. Hedge funds and other institutional investors own 74.90% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Stryker (SYK) Upgraded to Overweight at JPMorgan Chase & Co.” was originally published by American Market News and is the sole property of of American Market News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/02/stryker-syk-upgraded-to-overweight-at-jpmorgan-chase-co.html.
About Stryker
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
